Koji Takada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Koji Takada has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Shinichiro Kashiwagi
Department of Breast Surgical Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
23 shared publications - Kosei Hirakawa
Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
17 shared publications - Masaichi Ohira
Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
17 shared publications - Yuka Asano
Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
17 shared publications - Tsutomu Takashima
Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
16 shared publications - Wataru Goto
Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
16 shared publications
Latest Publications
- Open Access
- 1 August 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Treatment intensity modulation using S-1-based endocrine therapy in the era of oncotype DX: a real-world study
- 1 August 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessTreatment intensity modulation using S-1-based endocrine therapy in the era of oncotype DX: a real-world study
- 28 July 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 218 (2) , 21
Clinical and imaging factors associated with prolonged ablation time in radiofrequency ablation for early-stage breast cancer
- 28 July 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 218 (2) , 21
Clinical and imaging factors associated with prolonged ablation time in radiofrequency ablation for early-stage breast cancer
- Open Access
- 29 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Timing and clinical burden of febrile neutropenia and treatment discontinuation during neoadjuvant chemotherapy
Febrile neutropenia (FN) remains a major complication of neoadjuvant chemotherapy (NAC) and is a frequent cause of treatment disruption. However, FN is a h
- 29 June 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessTiming and clinical burden of febrile neutropenia and treatment discontinuation during neoadjuvant chemotherapy
Febrile neutropenia (FN) remains a major complication of neoadjuvant chemotherapy (NAC) and is a frequent cause of treatment disruption. However, FN is a h
- Open Access
- 6 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Clinical–genomic risk discordance and its impact on treatment selection in premenopausal women with node-positive hormone receptor-positive breast cancer
Purpose: The 21-gene Oncotype DX Recurrence Score (RS) is widely used to guide adjuvant chemotherapy decisions in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. However, the clinical interpretation of RS remains challenging in premenopausal women with node-positive disease, where discordance between genomic and clinicopathological risk is frequently encountered. This study aimed to elucidate the determinants of clinical–genomic risk discordance and to clarify its impact on real-world treatment selection, with a specific focus on premenopausal node-positive patients. Methods: We retrospectively analyzed 290 patients with HR+/HER2- breast cancer who underwent curative surgery and Oncotype DX testing between September 2023 and November 2025. Clinical risk was defined according to the St. Gallen criteria, and concordance or discordance was determined based on agreement or disagreement between clinical risk and RS. Logistic regression analyses were performed to identify predictors of discordance in the overall cohort and in node-positive patients. Treatment allocation was further examined in a predefined subgroup of 28 premenopausal patients with node-positive disease. Treatment strategies were categorized as chemotherapy plus endocrine therapy, endocrine therapy combined with systemic intensification (abemaciclib or S-1), or endocrine therapy alone. Results: Clinical–genomic risk discordance was observed in 123 patients (42.4%). In multivariable analysis of the overall cohort, larger tumor size (OR 8.33) and nodal positivity (OR 6.43) were independently associated with discordance, indicating a strong association with tumor burden. In contrast, among node-positive patients, premenopausal status (OR 0.18, p = 0.045) and high proliferative activity (Ki-67 > 20%; OR 4.81, p = 0.048) were independently associated with discordance, indicating a distinct biological pattern associated with proliferative activity in premenopausal disease. In the premenopausal node-positive subgroup, all concordant cases received intravenous chemotherapy, whereas discordant cases showed marked heterogeneity in treatment selection: chemotherapy in 2 patients (8.0%), endocrine therapy combined with targeted or fluoropyrimidine-based intensification strategies (including abemaciclib or S-1) in 11 patients (44.0%), and endocrine therapy alone in 12 patients ( p < 0.001). Conclusions: Clinical–genomic risk discordance is frequent in premenopausal women with node-positive hormone receptor-positive, HER2-negative breast cancer and is associated with distinct biological characteristics, including high proliferative activity. In real-world clinical practice, discordance was linked to substantial variation in adjuvant treatment selection, with many patients managed using endocrine-based strategies. These findings highlight the clinical relevance of integrating genomic and clinicopathological information in treatment decision-making and support the role of genomic assays as complementary tools for individualized therapy in this challenging population.
- 6 April 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessClinical–genomic risk discordance and its impact on treatment selection in premenopausal women with node-positive hormone receptor-positive breast cancer
Purpose: The 21-gene Oncotype DX Recurrence Score (RS) is widely used to guide adjuvant chemotherapy decisions in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. However, the clinical interpretation of RS remains challenging in premenopausal women with node-positive disease, where discordance between genomic and clinicopathological risk is frequently encountered. This study aimed to elucidate the determinants of clinical–genomic risk discordance and to clarify its impact on real-world treatment selection, with a specific focus on premenopausal node-positive patients. Methods: We retrospectively analyzed 290 patients with HR+/HER2- breast cancer who underwent curative surgery and Oncotype DX testing between September 2023 and November 2025. Clinical risk was defined according to the St. Gallen criteria, and concordance or discordance was determined based on agreement or disagreement between clinical risk and RS. Logistic regression analyses were performed to identify predictors of discordance in the overall cohort and in node-positive patients. Treatment allocation was further examined in a predefined subgroup of 28 premenopausal patients with node-positive disease. Treatment strategies were categorized as chemotherapy plus endocrine therapy, endocrine therapy combined with systemic intensification (abemaciclib or S-1), or endocrine therapy alone. Results: Clinical–genomic risk discordance was observed in 123 patients (42.4%). In multivariable analysis of the overall cohort, larger tumor size (OR 8.33) and nodal positivity (OR 6.43) were independently associated with discordance, indicating a strong association with tumor burden. In contrast, among node-positive patients, premenopausal status (OR 0.18, p = 0.045) and high proliferative activity (Ki-67 > 20%; OR 4.81, p = 0.048) were independently associated with discordance, indicating a distinct biological pattern associated with proliferative activity in premenopausal disease. In the premenopausal node-positive subgroup, all concordant cases received intravenous chemotherapy, whereas discordant cases showed marked heterogeneity in treatment selection: chemotherapy in 2 patients (8.0%), endocrine therapy combined with targeted or fluoropyrimidine-based intensification strategies (including abemaciclib or S-1) in 11 patients (44.0%), and endocrine therapy alone in 12 patients ( p < 0.001). Conclusions: Clinical–genomic risk discordance is frequent in premenopausal women with node-positive hormone receptor-positive, HER2-negative breast cancer and is associated with distinct biological characteristics, including high proliferative activity. In real-world clinical practice, discordance was linked to substantial variation in adjuvant treatment selection, with many patients managed using endocrine-based strategies. These findings highlight the clinical relevance of integrating genomic and clinicopathological information in treatment decision-making and support the role of genomic assays as complementary tools for individualized therapy in this challenging population.
- Open Access
- 28 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
Clinical characteristics and prognostic impact of HER2-ultralow breast cancer and tumor-infiltrating lymphocytes (TILs)
Purpose: HER2 expression is crucial in breast cancer classification and treatment. Traditionally, tumors were categorized as HER2-positive or HER2-negative, but HER2-low (IHC 1 + or 2 + without ISH amplification) has emerged as a new classification. Among HER2-negative cases, HER2-ultralow (≤ 10% faint HER2 staining) and HER2-null (completely HER2-negative) have been proposed. While differences between HER2-low and HER2-zero tumors are studied, little is known about the clinical and prognostic characteristics of HER2-ultralow breast cancer . This study aimed to clarify the clinical characteristics, immune microenvironment, treatment response, and prognosis of HER2-ultralow tumors, with HER2-null and HER2-low tumors analyzed as comparators . Methods: A retrospective analysis of 244 HER2-negative breast cancer patients treated with neoadjuvant chemotherapy (NAC) at Osaka Metropolitan University Hospital (2007–2018) classified tumors into HER2-low (41.0%), HER2-ultralow (36.1%), and HER2-null (23.0%). Clinicopathological features , tumor-infiltrating lymphocyte (TIL) counts , pathological complete response (pCR) , and prognostic outcomes (disease-free survival [DFS] and overall survival [OS]) were evaluated . Results: HER2-ultralow tumors showed significantly higher estrogen receptor (ER) positivity compared with HER2-null tumors (51.8% vs. 19.6%, p < 0.001), and also tended to have higher progesterone receptor positivity (p = 0.048). In contrast, HER2-null tumors were associated with younger age (median 50.0 vs. 56.0 years, p = 0.004) and higher TIL density (50.0% vs. 36.8%, p = 0.016). The overall pCR rate was 27.9%. DFS showed no significant differences among the three groups (p = 0.087), but OS was significantly worse in HER2-null compared with Not HER2-null tumors (p = 0.026, HR = 0.454). HER2-ultralow cases demonstrated an intermediate prognosis between HER2-low and HER2-null (OS comparison with HER2-null,>p= 0.101). Conclusion: HER2-ultralow tumors represent a distinct subgroup characterized by higher hormone receptor positivity , whereas HER2-null tumors were associated with younger age, higher TIL density, and poorer survival. These findings emphasize the clinical significance of refining HER2-negative subclassification to distinguish HER2-ultralow , while acknowledging limitations of sample size and retrospective design .
- 28 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1)
Open AccessClinical characteristics and prognostic impact of HER2-ultralow breast cancer and tumor-infiltrating lymphocytes (TILs)
Purpose: HER2 expression is crucial in breast cancer classification and treatment. Traditionally, tumors were categorized as HER2-positive or HER2-negative, but HER2-low (IHC 1 + or 2 + without ISH amplification) has emerged as a new classification. Among HER2-negative cases, HER2-ultralow (≤ 10% faint HER2 staining) and HER2-null (completely HER2-negative) have been proposed. While differences between HER2-low and HER2-zero tumors are studied, little is known about the clinical and prognostic characteristics of HER2-ultralow breast cancer . This study aimed to clarify the clinical characteristics, immune microenvironment, treatment response, and prognosis of HER2-ultralow tumors, with HER2-null and HER2-low tumors analyzed as comparators . Methods: A retrospective analysis of 244 HER2-negative breast cancer patients treated with neoadjuvant chemotherapy (NAC) at Osaka Metropolitan University Hospital (2007–2018) classified tumors into HER2-low (41.0%), HER2-ultralow (36.1%), and HER2-null (23.0%). Clinicopathological features , tumor-infiltrating lymphocyte (TIL) counts , pathological complete response (pCR) , and prognostic outcomes (disease-free survival [DFS] and overall survival [OS]) were evaluated . Results: HER2-ultralow tumors showed significantly higher estrogen receptor (ER) positivity compared with HER2-null tumors (51.8% vs. 19.6%, p < 0.001), and also tended to have higher progesterone receptor positivity (p = 0.048). In contrast, HER2-null tumors were associated with younger age (median 50.0 vs. 56.0 years, p = 0.004) and higher TIL density (50.0% vs. 36.8%, p = 0.016). The overall pCR rate was 27.9%. DFS showed no significant differences among the three groups (p = 0.087), but OS was significantly worse in HER2-null compared with Not HER2-null tumors (p = 0.026, HR = 0.454). HER2-ultralow cases demonstrated an intermediate prognosis between HER2-low and HER2-null (OS comparison with HER2-null,>p= 0.101). Conclusion: HER2-ultralow tumors represent a distinct subgroup characterized by higher hormone receptor positivity , whereas HER2-null tumors were associated with younger age, higher TIL density, and poorer survival. These findings emphasize the clinical significance of refining HER2-negative subclassification to distinguish HER2-ultralow , while acknowledging limitations of sample size and retrospective design .
- Open Access
- 17 February 2022
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 20 (1) , 1-13
Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
Background: Lymphocytes that surround cancer participate in tumor-related immune responses and are called tumor-infiltrating lymphocytes (TILs). Several recent reports suggest TILs index the tumor microenvironment and predict the therapeutic effect of chemotherapy. However, only few studies have studied the relationship between age and TILs. Aging reduces host immunity, and we predict that it may also affect TILs. Thus, we hypothesized that older breast cancer (BC) patients may have low TIL density than younger BC patients. Here, we retrospectively analyzed the differences in TILs by age and the therapeutic effects of preoperative chemotherapy (POC) in BC patients who were aged either less than 45 years or more than 60 years.Methods: We retrospectively examined the data of 356 breast cancer patients who underwent POC, including 75 patients aged ≤ 45 years and 116 patients aged > 60 years. Using pre-treatment needle biopsy specimens, TIL density was compared for each age group by Student’st-test. After analyzing different factors that affect TIL density, prognostic factors were also examined.Results: Older patients with triple-negative BC had significantly lower TIL density than younger patients, while in human epidermal growth factor receptor 2 (HER2)-enriched BC, TIL density was significantly higher in the younger age group than that in the older age group. In addition, younger patients with HER2-rich breast cancer showed significantly higher complete pathological response rates than older patients with HER2-rich BC. In addition, significant differences in overall survival were observed among these patients with triple-negative BC.Conclusions: Our study suggests that younger BC patients possess significantly higher TIL density than older patients. These differences may influence the therapeutic efficacy in highly immunogenic subtypes.
- 17 February 2022
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 20 (1) , 1-13
Open AccessDifferences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
Background: Lymphocytes that surround cancer participate in tumor-related immune responses and are called tumor-infiltrating lymphocytes (TILs). Several recent reports suggest TILs index the tumor microenvironment and predict the therapeutic effect of chemotherapy. However, only few studies have studied the relationship between age and TILs. Aging reduces host immunity, and we predict that it may also affect TILs. Thus, we hypothesized that older breast cancer (BC) patients may have low TIL density than younger BC patients. Here, we retrospectively analyzed the differences in TILs by age and the therapeutic effects of preoperative chemotherapy (POC) in BC patients who were aged either less than 45 years or more than 60 years.Methods: We retrospectively examined the data of 356 breast cancer patients who underwent POC, including 75 patients aged ≤ 45 years and 116 patients aged > 60 years. Using pre-treatment needle biopsy specimens, TIL density was compared for each age group by Student’st-test. After analyzing different factors that affect TIL density, prognostic factors were also examined.Results: Older patients with triple-negative BC had significantly lower TIL density than younger patients, while in human epidermal growth factor receptor 2 (HER2)-enriched BC, TIL density was significantly higher in the younger age group than that in the older age group. In addition, younger patients with HER2-rich breast cancer showed significantly higher complete pathological response rates than older patients with HER2-rich BC. In addition, significant differences in overall survival were observed among these patients with triple-negative BC.Conclusions: Our study suggests that younger BC patients possess significantly higher TIL density than older patients. These differences may influence the therapeutic efficacy in highly immunogenic subtypes.
- Open Access
- 20 October 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-13
Clinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy
Purpose: The body mass index (BMI) is commonly used as a simple indicator of obesity; patients with early-stage breast cancer who are obese (OB) per BMI measurements have been shown to have high postoperative recurrence and low survival rates. On the other hand, it has been shown that lymphocytes present in the vicinity of malignant growths that are involved in the tumors’ immune responses influence the efficacy chemotherapy. Therefore, we hypothesized that OB patients with breast cancer have a lower density of tumor-infiltrating lymphocytes (TILs), which may influence the therapeutic effect of preoperative chemotherapy (POC). In this study, we measured pretreatment BMI and TILs in patients with breast cancer who underwent POC, examined the correlations between these two factors, and retrospectively analyzed their therapeutic outcomes and prognoses. Methods: The participants in this study were 421 patients with breast cancer who underwent surgical treatment after POC between February 2007 and January 2019. The patient’s height and weight were measured before POC to calculate the BMI (weight [kg] divided by the square of the height [m2]). According to the World Health Organization categorization, patients who weighed under 18.5 kg/m2 were classified as underweight (UW), those ≥18.5 kg/m2 and > 25 kg/m2 were considered normal weight (NW), those ≥25 kg/m2 and < 30 kg/m2 were overweight (OW), and those ≥30 kg/m2 were OB. The TILs were those lymphocytes that infiltrated the tumor stroma according to the definition of the International TILs Working Group 2014. Results: The median BMI was 21.9 kg/m2 (range, 14.3–38.5 kg/m2); most patients (244; 64.5%) were NW. Among all 378 patients with breast cancer, the TIL density was significantly lower in OB than in NW and OW patients (vs. NW: p = 0.001; vs. OW: p = 0.003). Furthermore, when examining patients with each breast cancer type individually, the OS of those with TNBC who had low BMIs was significantly poorer than that of their high-BMI counterparts (log rank p = 0.031). Conclusions: Our data did not support the hypothesis that obesity affects the tumor immune microenvironment; however, we showed that being UW does affect the tumor immune microenvironment.
- 20 October 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-13
Open AccessClinical verification of body mass index and tumor immune response in patients with breast cancer receiving preoperative chemotherapy
Purpose: The body mass index (BMI) is commonly used as a simple indicator of obesity; patients with early-stage breast cancer who are obese (OB) per BMI measurements have been shown to have high postoperative recurrence and low survival rates. On the other hand, it has been shown that lymphocytes present in the vicinity of malignant growths that are involved in the tumors’ immune responses influence the efficacy chemotherapy. Therefore, we hypothesized that OB patients with breast cancer have a lower density of tumor-infiltrating lymphocytes (TILs), which may influence the therapeutic effect of preoperative chemotherapy (POC). In this study, we measured pretreatment BMI and TILs in patients with breast cancer who underwent POC, examined the correlations between these two factors, and retrospectively analyzed their therapeutic outcomes and prognoses. Methods: The participants in this study were 421 patients with breast cancer who underwent surgical treatment after POC between February 2007 and January 2019. The patient’s height and weight were measured before POC to calculate the BMI (weight [kg] divided by the square of the height [m2]). According to the World Health Organization categorization, patients who weighed under 18.5 kg/m2 were classified as underweight (UW), those ≥18.5 kg/m2 and > 25 kg/m2 were considered normal weight (NW), those ≥25 kg/m2 and < 30 kg/m2 were overweight (OW), and those ≥30 kg/m2 were OB. The TILs were those lymphocytes that infiltrated the tumor stroma according to the definition of the International TILs Working Group 2014. Results: The median BMI was 21.9 kg/m2 (range, 14.3–38.5 kg/m2); most patients (244; 64.5%) were NW. Among all 378 patients with breast cancer, the TIL density was significantly lower in OB than in NW and OW patients (vs. NW: p = 0.001; vs. OW: p = 0.003). Furthermore, when examining patients with each breast cancer type individually, the OS of those with TNBC who had low BMIs was significantly poorer than that of their high-BMI counterparts (log rank p = 0.031). Conclusions: Our data did not support the hypothesis that obesity affects the tumor immune microenvironment; however, we showed that being UW does affect the tumor immune microenvironment.
- Open Access
- 26 June 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-13
Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer
Background: Lymph node metastasis is more likely in early-stage breast cancer with lower tumor-infiltrating lymphocyte (TIL) density. Therefore, we investigated the correlation between TILs and lymph node metastasis in cT1 breast cancer patients undergoing surgery and the usefulness of TILs in predicting sentinel lymph node metastasis (SLNM) in cT1N0M0 breast cancer. Methods: We investigated 332 breast cancer patients who underwent surgery as the first-line treatment after preoperative diagnosis of cT1. A positive diagnosis of SLNM as an indication for axillary clearance was defined as macrometastasis in the sentinel lymph node (SLN) (macrometastasis: tumor diameter > 2 mm). Semi-quantitative evaluation of lymphocytes infiltrating the peritumoral stroma as TILs in primary tumor biopsy specimens prior to treatment was conducted. Results: For SLN biopsy (SLNB), a median of 2 (range, 1–8) SLNs were pathologically evaluated. Sixty cases (19.4%) of SLNM (macrometastasis: 46, micrometastasis: 16) were observed. Metastasis was significantly greater in breast cancers with tumor diameter > 10 mm than in those with diameter ≤ 10 mm (p = 0.016). Metastasis was significantly associated with lymphatic invasion (p < 0.001). These two clinicopathological factors correlated with SLNM even in patients diagnosed with cN0 (tumor size; p = 0.017, lymphatic invasion; p = 0.002). Multivariate analysis for SLNM predictors revealed lymphatic invasion (p = 0.008, odds ratio [OR] = 2.522) and TILs (p < 0.001, OR = 0.137) as independent factors. Conclusions: Our results suggest a correlation between lymph node metastasis and tumor immune-microenvironment in cT1 breast cancer. TIL density may be a predictor of SLNM in breast cancer without lymph node metastasis on preoperative imaging.
- 26 June 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-13
Open AccessPrediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer
Background: Lymph node metastasis is more likely in early-stage breast cancer with lower tumor-infiltrating lymphocyte (TIL) density. Therefore, we investigated the correlation between TILs and lymph node metastasis in cT1 breast cancer patients undergoing surgery and the usefulness of TILs in predicting sentinel lymph node metastasis (SLNM) in cT1N0M0 breast cancer. Methods: We investigated 332 breast cancer patients who underwent surgery as the first-line treatment after preoperative diagnosis of cT1. A positive diagnosis of SLNM as an indication for axillary clearance was defined as macrometastasis in the sentinel lymph node (SLN) (macrometastasis: tumor diameter > 2 mm). Semi-quantitative evaluation of lymphocytes infiltrating the peritumoral stroma as TILs in primary tumor biopsy specimens prior to treatment was conducted. Results: For SLN biopsy (SLNB), a median of 2 (range, 1–8) SLNs were pathologically evaluated. Sixty cases (19.4%) of SLNM (macrometastasis: 46, micrometastasis: 16) were observed. Metastasis was significantly greater in breast cancers with tumor diameter > 10 mm than in those with diameter ≤ 10 mm (p = 0.016). Metastasis was significantly associated with lymphatic invasion (p < 0.001). These two clinicopathological factors correlated with SLNM even in patients diagnosed with cN0 (tumor size; p = 0.017, lymphatic invasion; p = 0.002). Multivariate analysis for SLNM predictors revealed lymphatic invasion (p = 0.008, odds ratio [OR] = 2.522) and TILs (p < 0.001, OR = 0.137) as independent factors. Conclusions: Our results suggest a correlation between lymph node metastasis and tumor immune-microenvironment in cT1 breast cancer. TIL density may be a predictor of SLNM in breast cancer without lymph node metastasis on preoperative imaging.
- Open Access
- 3 June 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-9
Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ
Background: Invasion is often found during postoperative pathological examination of cases diagnosed as ductal carcinoma in situ (DCIS) by histological examinations such as core needle biopsy (CNB) or vacuum-assisted biopsy (VAB). A meta-analysis reported that 25.9% of invasive ductal carcinoma (IDC) cases are preoperatively diagnosed by CNB as DCIS. Risk factors for invasion have been studied by postoperative examination, but no factors have been found that could be obtained preoperatively from blood tests. In this study, we investigated factors predictive of invasion based on preoperative blood tests in patients diagnosed with DCIS by preoperative biopsy. Methods: In this study, 118 patients who were diagnosed with DCIS by preoperative biopsy were included. Biopsies were performed with 16-gauge CNB or VAB. Peripheral blood was obtained at the time of diagnosis. This study evaluated absolute platelet count, absolute lymphocyte count, lactate dehydrogenase, carcinoembryonic antigen, and cancer antigen 15–3 (CA15–3). The platelet–lymphocyte ratio (PLR) was calculated by dividing the absolute platelet count by the absolute lymphocyte count, and patients were grouped into high PLR (≥160.0) and low PLR (< 160.0) groups. Results: Invasion was found more frequently after surgery in pathologically high-grade cases than in pathologically not-high-grade cases (p = 0.015). The median PLR was 138.9 and 48 patients (40.7%) were classified into the high PLR group. The high PLR group was significantly more likely to have invasion detected by the postoperative pathology than the low PLR group (p = 0.018). In multivariate analysis of factors predictive of invasion in postoperative pathology, a high PLR (p = 0.006, odds ratio [OR] = 3.526) and biopsy method (VAB vs. CNB, p = 0.001, OR = 0.201) was an independent risk factor. Conclusions: The PLR may be a predictor of invasion in the postoperative pathology for patients diagnosed with DCIS by preoperative biopsy.
- 3 June 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-9
Open AccessFactors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ
Background: Invasion is often found during postoperative pathological examination of cases diagnosed as ductal carcinoma in situ (DCIS) by histological examinations such as core needle biopsy (CNB) or vacuum-assisted biopsy (VAB). A meta-analysis reported that 25.9% of invasive ductal carcinoma (IDC) cases are preoperatively diagnosed by CNB as DCIS. Risk factors for invasion have been studied by postoperative examination, but no factors have been found that could be obtained preoperatively from blood tests. In this study, we investigated factors predictive of invasion based on preoperative blood tests in patients diagnosed with DCIS by preoperative biopsy. Methods: In this study, 118 patients who were diagnosed with DCIS by preoperative biopsy were included. Biopsies were performed with 16-gauge CNB or VAB. Peripheral blood was obtained at the time of diagnosis. This study evaluated absolute platelet count, absolute lymphocyte count, lactate dehydrogenase, carcinoembryonic antigen, and cancer antigen 15–3 (CA15–3). The platelet–lymphocyte ratio (PLR) was calculated by dividing the absolute platelet count by the absolute lymphocyte count, and patients were grouped into high PLR (≥160.0) and low PLR (< 160.0) groups. Results: Invasion was found more frequently after surgery in pathologically high-grade cases than in pathologically not-high-grade cases (p = 0.015). The median PLR was 138.9 and 48 patients (40.7%) were classified into the high PLR group. The high PLR group was significantly more likely to have invasion detected by the postoperative pathology than the low PLR group (p = 0.018). In multivariate analysis of factors predictive of invasion in postoperative pathology, a high PLR (p = 0.006, odds ratio [OR] = 3.526) and biopsy method (VAB vs. CNB, p = 0.001, OR = 0.201) was an independent risk factor. Conclusions: The PLR may be a predictor of invasion in the postoperative pathology for patients diagnosed with DCIS by preoperative biopsy.
- Open Access
- 5 April 2020
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 18 (1) , 1-12
The effect of smoking on biological change of recurrent breast cancer
Background: The selection of treatment for a patient with breast cancer largely relies on the cancer subtype. However, this process is complicated by changes in tumor biology at relapse. Smoking has been identified as a risk factor for breast cancer. The direct effect of a tobacco component delivered via blood circulation on the mammary gland tissue and subsequent DNA damage have been proposed to explain the association between cigarette smoking and breast cancer carcinogenesis. This postulation is supported by both tissue culture and animal studies demonstrating that the associated DNA damage further alters breast cancer cells, as indicated by an increased proliferative capacity and malignant transformation. In this study, we aimed to explore the relationship between changes in Estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) each receptor at recurrence, and smoking and the prognosis after recurrence. Methods: This retrospective study included 989 patients with primary breast cancer who developed relapse after surgery and 50 patients who underwent regenerative biopsy or surgery from December 2007 to March 2018. ER, PgR, and HER2 expression in the primary and recurrent lesions was evaluated using immunohistochemistry, and the correlations of these expression patterns with smoking history (pack-years) were examined. Results: When ER was evaluated in recurrent tumors, negative and positive conversions were recognized in 3 (6.0%) and 1 patient (2.0%), respectively. When PgR was evaluated, negative conversion was recognized in 15 patients (30.0%). When HER2 was evaluated, positive conversion was recognized in 6 patients (12.0%). Consequently, we observed a change in the intrinsic subtype in in 5 patients with recurrent tumors (10.0%). Although most clinical factors were not correlated with smoking, a positive conversion of HER2 in recurrence was significantly more frequent among smokers than among non-smokers (p = 0.024). Conclusions: Biological changes during breast cancer recurrence should be given careful clinical consideration because they affect treatment after recurrence. Our results suggest that smoking may induce increased HER2 expression in recurrent breast tumors.
- 5 April 2020
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 18 (1) , 1-12
Open AccessThe effect of smoking on biological change of recurrent breast cancer
Background: The selection of treatment for a patient with breast cancer largely relies on the cancer subtype. However, this process is complicated by changes in tumor biology at relapse. Smoking has been identified as a risk factor for breast cancer. The direct effect of a tobacco component delivered via blood circulation on the mammary gland tissue and subsequent DNA damage have been proposed to explain the association between cigarette smoking and breast cancer carcinogenesis. This postulation is supported by both tissue culture and animal studies demonstrating that the associated DNA damage further alters breast cancer cells, as indicated by an increased proliferative capacity and malignant transformation. In this study, we aimed to explore the relationship between changes in Estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) each receptor at recurrence, and smoking and the prognosis after recurrence. Methods: This retrospective study included 989 patients with primary breast cancer who developed relapse after surgery and 50 patients who underwent regenerative biopsy or surgery from December 2007 to March 2018. ER, PgR, and HER2 expression in the primary and recurrent lesions was evaluated using immunohistochemistry, and the correlations of these expression patterns with smoking history (pack-years) were examined. Results: When ER was evaluated in recurrent tumors, negative and positive conversions were recognized in 3 (6.0%) and 1 patient (2.0%), respectively. When PgR was evaluated, negative conversion was recognized in 15 patients (30.0%). When HER2 was evaluated, positive conversion was recognized in 6 patients (12.0%). Consequently, we observed a change in the intrinsic subtype in in 5 patients with recurrent tumors (10.0%). Although most clinical factors were not correlated with smoking, a positive conversion of HER2 in recurrence was significantly more frequent among smokers than among non-smokers (p = 0.024). Conclusions: Biological changes during breast cancer recurrence should be given careful clinical consideration because they affect treatment after recurrence. Our results suggest that smoking may induce increased HER2 expression in recurrent breast tumors.